12.09.2016 • NewsDede WillamsBayerMonsanto

Bayer to Divest Dermatology Arm?

As it prepares to pay a higher price to acquire US agrochemicals giant Monsanto – if it comes to a deal at all  – Bayer is said to be exploring the sale of its dermatology business. Bayer is working with JPMorgan Chase & Co on the sale, which could bring in more than €1 billion, sources cited by the news agency Bloomberg said.

Analysts told Bloomberg the dermatology business, most of which was picked up in the 2006 aquisition of former Berlin-based drugmaker Schering, could attract interest from existing manufacturers of skincare products including Nestle’s, Allergan and Almirall as well as private equity firms, Bloomberg’s sources suggested. 

Since announcing plans to acquire Monsanto, observers have also mooted that the Germany-based group could also shed its animal health business.

Virtual Event

DIGITALIZATION IN THE CHEMICAL INDUSTRY

DIGITALIZATION IN THE CHEMICAL INDUSTRY

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.